NEW YORK, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have
commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead
plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links
provided. There is no cost or obligation to you.
Tenaris S.A. (NYSE: TS)
Class Period: May 1, 2014 - November 27, 2018
Lead Plaintiff Deadline: February 11, 2019
Join the action: https://www.zlk.com/pslra-1/tenaris-s-a-loss-form?wire=3
About the lawsuit: Throughout the class period, Tenaris S.A. allegedly made materially false and/or misleading statements and/or
failed to disclose that: (1) Tenaris’s CEO and Chairman, Paolo Rocca, knew that one of his company’s executives paid cash to
government officials from 2009 to 2012 to expedite compensation payments for the sale of Sidor; (2) this conduct would lead to
Rocca being charged in a graft scheme, and subject Tenaris, its affiliates, and/or executives to heightened governmental scrutiny;
and (3) as a result, Tenaris’s public statements were materially false and/or misleading at all relevant times. When the true
details entered the market, the lawsuit claims that investors suffered damages.
To learn more about the Tenaris S.A. class action contact jlevi@levikorsinsky.com.
Immunomedics, Inc. (NASDAQ: IMMU)
Class Period: August 23, 2018 - December 20, 2018
Lead Plaintiff Deadline: February 25, 2019
Join the action: https://www.zlk.com/pslra-1/immunomedics-inc-loss-form?wire=3
The complaint alleges that, throughout the class period, defendants made false and misleading statements. The United States Food
& Drug Administration issued citations against Immunomedics for multiple violations at its Morris Plains, New Jersey facility. The
FDA citations included the manipulation of bioburden samples, backdating of records, and misrepresentation of integrity test
procedures. Based on these facts, the Company’s public statements were false and materially misleading throughout the class
period. On December 17, 2018, FDAnews.com published an article entitled “FDA Hits Immunomedics for Data Integrity
Breach.” Upon this news, Immunomedics’ stock price fell sharply, damaging investors.
To learn more about the Immunomedics, Inc. class action contact jlevi@levikorsinsky.com.
Ferroglobe PLC (NASDAQ: GSM)
Class Period: August 21, 2018 - November 26, 2018
Lead Plaintiff Deadline: March 25, 2019
Join the action: https://www.zlk.com/pslra-1/ferroglobe-plc-loss-form?wire=3
About the lawsuit: Ferroglobe PLC allegedly made materially false and/or misleading statements and/or failed to disclose that:
(1) there was excess supply of the Company’s products; (2) demand for the Company’s products was declining; (3) as a result, the
pricing of the Company’s products would be materially impacted; and (4) as a result of the foregoing, Defendants’ positive
statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable
basis.
To learn more about the Ferroglobe PLC class action contact jlevi@levikorsinsky.com.
Tyme Technologies, Inc. (NASDAQCM: TYME)
Class Period: March 14, 2018 - January 18, 2019
Lead Plaintiff Deadline: March 29, 2019
Join the action: https://www.zlk.com/pslra-1/tyme-technologies-inc-loss-form?wire=3
About the lawsuit: During the class period, Tyme Technologies, Inc. allegedly made materially false and/or misleading statements
and/or failed to disclose that: (i) Tyme had not adequately designed the Phase II Study to present reliable results on the efficacy
of SM-88 on pancreatic cancer; (ii) Tyme had failed to include an appropriate control group in its open-label Phase II clinical
trial for SM-88; (iii) the omission of an appropriate control group distorted the reliability of data showing the efficacy of SM-88
in the Phase II Study; and (iv) as a result, Tyme’s public statements were materially false and misleading at all relevant
times.
To learn more about the Tyme Technologies, Inc. class action contact jlevi@levikorsinsky.com.
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any
recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys
have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of
dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
